Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $11.94.

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported disappointing fourth-quarter results: its EPS missed significantly, and its full ...

Wall Street analysts expect 10x Genomics (TXG) to post quarterly loss of $0.32 per share in its upcoming report, which indicates a year-over-year increase of 22%. Revenues are expected to be $158. ...

He is the author of “The Myth of Voter Suppression: The Left’s Assault on Clean Elections.” Send an email to Fred. Legacy media outlets and liberal interest groups have recently claimed that ...

The PC version announcement also comes with the addition of a collaboration between Stellar Blade and the iOS title Goddess of Victory: Nikke, which is coming soon. This marks the second ...

The White House slammed Democratic Sen. Chris Murphy as a "moron" on social media after the Connecticut lawmaker posted an expletive-riddled admonishment against a Lara Trump parody account he ...

Stellar Blade developer Shift Up expects the forthcoming PC release of its action game to exceed sales of the console release. As part of its latest financial report, the company was asked about ...

In trading on Monday, shares of 10x Genomics Inc (Symbol: TXG) entered into oversold territory, hitting an RSI reading of 27.9, after changing hands as low as $11.8955 per share. By comparison ...

Stellar Blade has a PC release on the way, due in June this year with additional content. The sci-fi action game released last year on PS5 and has proven to be a massive success for its developer ...